NEW YORK — Aspirin has shown remarkable promise in treating colon cancer in people with mutations in a gene that’s thought to play a role in the disease.
Among patients with the mutations, those who regularly took aspirin lived longer than those who didn’t, a major study found. Five years after their cancers were diagnosed, 97 percent of the aspirin users were still alive versus 74 percent of those not taking the drug.
Aspirin seemed to make no difference in patients who did not have the mutations.
This sort of study can’t prove that aspirin caused the better survival, and doctors say more research must confirm the findings before aspirin can be recommended more widely. The study wasn’t designed to test aspirin; people were taking it on their own for various reasons.
Still, the results suggest that this simple medicine might be the cheapest gene-targeting therapy ever found for cancer. About one-sixth of all colon cancer patients have the mutated gene and might be helped by aspirin.
“It’s exciting to think that something that’s already in the medicine cabinet may really have an important effect” beyond relieving pain and helping to prevent heart attacks, said Dr. Andrew Chan of Massachusetts General Hospital. He and others from Harvard Medical School led the study.
Cancers of the colon or rectum are a leading cause of cancer deaths worldwide. More than 140,000 new cases and 51,000 deaths from them are expected this year in the United States.
Several studies suggest that aspirin may help fight cancer, especially colorectal tumors. It is often recommended for people who have colon cancer and others at high risk of developing it. But it’s not advised for wider use, or for cancer prevention, because it can cause serious bleeding in the stomach and gut.
What has been lacking, doctors say, is a good way to tell which people might benefit the most, so aspirin’s risks would be justified. Chan’s study suggests a way to do that.
It involved 964 people diagnosed with various stages of colon cancer who were among nearly 175,000 participants in two health studies based at Harvard that began in the 1980s. Every two years, they filled out surveys on their health habits, including aspirin use.
Most had surgery for their cancer, and many also had chemotherapy. They gave tumor tissue samples that could be tested for gene activity. Researchers focused on one gene, PIK3CA, that is involved in a key pathway that fuels cancer’s growth and spread. Aspirin seems to blunt that pathway, so the scientists looked at its use.
In those whose tumors had a mutation in that gene, regular aspirin use cut the risk of dying of colon cancer by 82 percent and of dying of any cause by 46 percent during the study period of about 13 years.
For local news and more, subscribe to The Norman Transcript Smart Edition, or our print edition.
Probe Begins After Conn. Commuter Trains Crash
NTSB Begins Investigation Into Conn. Train Crash
Lotto Fever Sweeps the Country
Conn. Commuter Trains Collide; 60 Go to Hospital
Coffee Run Leads to Hatchet Hitchhiker Arrest
Fmr. IRS Head Insists No Politics in Targeting
CDC: Fecal Bacteria Common in Swimming Pools
$1 Million in Jewels Stolen at Cannes Film Fest
NM Mom Chases Down Child Abductor
Raw: Crash Sends Car Into Fla. Pool
Raw: Obama Sits Down With Elementary Kids
Raw: Bear Falls From Tampa Tree
Ousted IRS Chief: Errors Not Caused by Politics
Terror Suspect Due in Court in Idaho Friday
Raw: Driver Ejected From Truck, Over Bridge
Could Tobacco Be the Next Biofuel?
Wash. State Releases Draft Rules for Legal Pot
Dying Man's Blinks Lead to Murder Conviction
Officials: Texas Tornado Likely Had 200 Mph Wind
Brothers Arrested in NOLA Parade Shooting
